Literature DB >> 8979771

Pharmacology of adenosine A2A receptors.

E Ongini1, B B Fredholm.   

Abstract

Adenosine A2A receptors, which have been cloned from several mammalian species, are activated by physiological concentrations of adenosine to stimulate the formation of cAMP and other mediators. The A2A receptors are found on neutrophil leukocytes, platelets, blood vessels and, very abundantly, on some cells in the CNS. In the caudate nucleus they coexist with dopamine D2 receptors, and stimulation of A2A receptors causes a decrease in D2 receptor-mediated neurotransmission. Thus, drugs that act on A2A receptors can be used to modify dopaminergic neurotransmission known to be important in neurological and psychiatric disorders. In this review, Ennio Ongini and Bertil Fredholm describe how recently developed potent and selective A2A receptor antagonists can be used to delineate the physiological and pathological processes regulated by A2A receptors. Results from in vitro and in vivo pharmacology studies strengthen the notion that A2A receptors are an interesting target for drug development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8979771

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  52 in total

1.  Adenosine mediates relaxation of human small resistance-like coronary arteries via A2B receptors.

Authors:  B K Kemp; T M Cocks
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

Review 2.  A(2A) adenosine receptors in human peripheral blood cells.

Authors:  S Gessi; K Varani; S Merighi; E Ongini; P A Borea
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

3.  Accelerated resequestration of cytosolic calcium and suppression of the pro-inflammatory activities of human neutrophils by CGS 21680 in vitro.

Authors:  R Anderson; S S Visser; G Ramafi; A J Theron
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

4.  A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice.

Authors:  J F Chen; Z Huang; J Ma; J Zhu; R Moratalla; D Standaert; M A Moskowitz; J S Fink; M A Schwarzschild
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

5.  Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists.

Authors:  G W Sullivan; J M Rieger; W M Scheld; T L Macdonald; J Linden
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

6.  Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation.

Authors:  A M Sebastião; A de Mendonca; T Moreira; J A Ribeiro
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

7.  Functional uncoupling of adenosine A(2A) receptors and reduced responseto caffeine in mice lacking dopamine D2 receptors.

Authors:  N R Zahniser; J K Simosky; R D Mayfield; C A Negri; T Hanania; G A Larson; M A Kelly; D K Grandy; M Rubinstein; M J Low; B B Fredholm
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

Review 8.  Growth hormone secretagogue receptor family members and ligands.

Authors:  R G Smith; R Leonard; A R Bailey; O Palyha; S Feighner; C Tan; K K Mckee; S S Pong; P Griffin; A Howard
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

9.  Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.

Authors:  Jordi Bové; Jordi Serrats; Guadalupe Mengod; Roser Cortés; Eduardo Tolosa; Concepció Marin
Journal:  Exp Brain Res       Date:  2005-06-21       Impact factor: 1.972

10.  Human breast cancer cell line MDA-MB-231 expresses endogenous A2B adenosine receptors mediating a Ca2+ signal.

Authors:  Mojtaba Panjehpour; Marián Castro; Karl-Norbert Klotz
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.